A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer.

被引：2
|
作者：
Beatty, G. L.
Chiorean, E. G.
Torigian, D. A.
Teitelbaum, U. R.
Sun, W.
Fly, K. D.
Huhn, R. D.
Vonderheide, R. H.
O'Dwyer, P. J.
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[3] Univ Penn, Philadelphia, PA 19104 USA
[4] Pfizer Inc, New London, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2539
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
    Laura A. Vitale
    Lawrence J. Thomas
    Li-Zhen He
    Thomas O’Neill
    Jenifer Widger
    Andrea Crocker
    Karuna Sundarapandiyan
    James R. Storey
    Eric M. Forsberg
    Jeffrey Weidlick
    April R. Baronas
    Lauren E. Gergel
    James M. Boyer
    Crystal Sisson
    Joel Goldstein
    Henry C. Marsh
    Tibor Keler
    Cancer Immunology, Immunotherapy, 2019, 68 : 233 - 245
  • [22] Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
    Thomas, Lawrence
    Vitale, Laura
    O'Neill, Thomas
    Widger, Jenifer
    Crocker, Andrea
    He, Li-Zhen
    Weidlick, Jeffrey
    Sundarapandiyan, Karuna
    Storey, James
    Forsberg, Eric
    Pilsmaker, Catherine
    Gergel, Lauren
    Do, Elizabeth
    Goldstein, Joel
    Marsh, Henry
    Keler, Tibor
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [23] Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
    Vitale, Laura A.
    Thomas, Lawrence J.
    He, Li-Zhen
    O'Neill, Thomas
    Widger, Jenifer
    Crocker, Andrea
    Sundarapandiyan, Karuna
    Storey, James R.
    Forsberg, Eric M.
    Weidlick, Jeffrey
    Baronas, April R.
    Gergel, Lauren E.
    Boyer, James M.
    Sisson, Crystal
    Goldstein, Joel
    Marsh, Henry C., Jr.
    Keler, Tibor
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (02) : 233 - 245
  • [24] Phase I study of recombinant human CD40 ligand in cancer patients
    Vonderheide, RH
    Dutcher, JP
    Anderson, JE
    Eckhardt, SG
    Stephans, KF
    Razvillas, B
    Garl, S
    Butine, MD
    Perry, VP
    Armitage, RJ
    Ghalie, R
    Caron, DA
    Gribben, JG
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3280 - 3287
  • [25] Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice
    Aghevlian, Sadaf
    Wu, Bo
    Raie, Marina Nura
    Tumbale, Spencer K.
    Kare, Aris J.
    Seo, Jai W.
    Ferrara, Katherine W.
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 98-99 : 8 - 17
  • [26] Phase II study of gemcitabine and Flutamide in advanced pancreatic cancer.
    Mayer, A
    Shaw, J
    D'Ath, S
    Price, P
    Blesing, C
    Corrie, P
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [27] Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
    Johnson, Peter
    Challis, Ruth
    Chowdhury, Ferdousi
    Gao, Yifang
    Harvey, Melanie
    Geldart, Tom
    Kerr, Paul
    Chan, Claude
    Smith, Anna
    Steven, Neil
    Edwards, Ceri
    Ashton-Key, Margaret
    Hodges, Elisabeth
    Tutt, Alison
    Ottensmeier, Christian
    Glennie, Martin
    Williams, Anthony
    CLINICAL CANCER RESEARCH, 2015, 21 (06) : 1321 - 1328
  • [28] Phase II study of CP-4126, a gemcitabine-lipid conjugate, in patients with advanced pancreatic cancer.
    Ikdahl, T.
    Dueland, S.
    Hendlisz, A.
    Dajani, O.
    Brunsvig, P.
    Awada, A.
    Rao, J.
    Farrell, J.
    Rasch, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Moreno, Victor
    Perets, Ruth
    Peretz-Yablonski, Tamar
    Fourneau, Nele
    Girgis, Suzette
    Guo, Yue
    Hellemans, Peter
    Verona, Raluca
    Pendas, Natalia
    Xia, Qi
    Geva, Ravit
    Calvo, Emiliano
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 93 - 104
  • [30] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Victor Moreno
    Ruth Perets
    Tamar Peretz-Yablonski
    Nele Fourneau
    Suzette Girgis
    Yue Guo
    Peter Hellemans
    Raluca Verona
    Natalia Pendás
    Qi Xia
    Ravit Geva
    Emiliano Calvo
    Investigational New Drugs, 2023, 41 : 93 - 104
12345